Key takeaway
Across 19 randomised trials with 145 939 participants, lowering systolic blood pressure by 5 mm Hg reduced new-onset type 2 diabetes by 11% (HR 0.89, 95% CI 0.84-0.95), though drug classes differed: ACE inhibitors and ARBs lowered risk, while beta blockers and thiazide diuretics raised it. The trials were run between 1973 and 2008 and were not designed to test diabetes prevention, so diabetes was not the original main endpoint.
Study design
Evidence review
Reading basis
Published abstract
Reading focus
Design & applicability
The research question
Blood pressure lowering is known to prevent complications in people who already have diabetes, but whether it also prevents diabetes is unclear. The authors used participant-level data from major randomised trials to test the effect of lowering blood pressure itself, and the differing effects of five main antihypertensive drug classes, on new-onset type 2 diabetes.
Who and how
Individual participant data meta-analysis by the Blood Pressure Lowering Treatment Trialists' Collaboration, using 22 studies conducted between 1973 and 2008. Trials had to compare a drug class with placebo or another class and have at least 1000 person-years of follow-up per arm; people with diabetes at baseline were excluded. A one-stage meta-analysis (19 trials) used a stratified Cox model for the effect of blood pressure lowering, and a network meta-analysis (22 trials) used logistic regression to compare drug classes. Median follow-up was 4.5 years (IQR 2.0).
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Among 145 939 participants (88 500 men and 57 429 women), 9883 were diagnosed with new-onset type 2 diabetes.
- 2A 5 mm Hg reduction in systolic blood pressure reduced the risk of type 2 diabetes by 11% (HR 0.89, 95% CI 0.84-0.95).
- 3Compared with placebo, angiotensin-converting enzyme inhibitors (RR 0.84, 95% CI 0.76-0.93) and angiotensin II receptor blockers (RR 0.84, 95% CI 0.76-0.92) reduced risk.
- 4Beta blockers (RR 1.48, 95% CI 1.27-1.72) and thiazide diuretics (RR 1.20, 95% CI 1.07-1.35) increased risk, and calcium channel blockers had no material effect (RR 1.02, 95% CI 0.92-1.13).
Limits & uncertainty
- 1Trials ran from 1973 to 2008 and median follow-up was only 4.5 years, so current practice and long-term effects may differ.
- 2The trials enrolled people with hypertension or cardiovascular risk and excluded those with diabetes at baseline, so the results do not apply to people with normal blood pressure.
- 3Drug-class comparisons came from a network meta-analysis, and the abstract does not report how new-onset diabetes was ascertained in each trial.
- 4The drug differences are attributed by the authors to off-target effects, which this analysis did not test. This reading is based on the abstract only.
What to take from it
For people who need blood pressure treatment, drug choice may matter for later diabetes risk, with ACE inhibitors and ARBs looking most favourable here, but beta blockers and thiazides are still used for good reasons. Do not stop or switch medication because of this finding. Decisions about blood pressure treatment belong with your clinician.
Reading your own data
A home blood pressure cuff, read at the same time of day and posture, lets you and your clinician see whether your average is moving, which is the exposure studied here. Weight and fasting glucose logs can add context for diabetes risk, and trends over weeks matter more than a single reading.
How to read this evidence
Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Background
Blood pressure lowering is an established strategy for preventing microvascular and macrovascular complications of diabetes, but its role in the prevention of diabetes itself is unclear. We aimed to examine this question using individual participant data from major randomised controlled trials.
Methods
We performed a one-stage individual participant data meta-analysis, in which data were pooled to investigate the effect of blood pressure lowering per se on the risk of new-onset type 2 diabetes. An individual participant data network meta-analysis was used to investigate the differential effects of five major classes of antihypertensive drugs on the risk of new-onset type 2 diabetes. Overall, data from 22 studies conducted between 1973 and 2008, were obtained by the Blood Pressure Lowering Treatment Trialists' Collaboration (Oxford University, Oxford, UK). We included all primary and secondary prevention trials that used a specific class or classes of antihypertensive drugs versus placebo or other classes of blood pressure lowering medications that had at least 1000 persons-years of follow-up in each randomly allocated arm. Participants with a known diagnosis of diabetes at baseline and trials conducted in patients with prevalent diabetes were excluded. For the one-stage individual participant data meta-analysis we used stratified Cox proportional hazards model and for the individual participant data network meta-analysis we used logistic regression models to calculate the relative risk (RR) for drug class comparisons.
Findings
145 939 participants (88 500 [60·6%] men and 57 429 [39·4%] women) from 19 randomised controlled trials were included in the one-stage individual participant data meta-analysis. 22 trials were included in the individual participant data network meta-analysis. After a median follow-up of 4·5 years (IQR 2·0), 9883 participants were diagnosed with new-onset type 2 diabetes. Systolic blood pressure reduction by 5 mm Hg reduced the risk of type 2 diabetes across all trials by 11% (hazard ratio 0·89 [95% CI 0·84-0·95]). Investigation of the effects of five major classes of antihypertensive drugs showed that in comparison to placebo, angiotensin-converting enzyme inhibitors (RR 0·84 [95% 0·76-0·93]) and angiotensin II receptor blockers (RR 0·84 [0·76-0·92]) reduced the risk of new-onset type 2 diabetes; however, the use of β blockers (RR 1·48 [1·27-1·72]) and thiazide diuretics (RR 1·20 [1·07-1·35]) increased this risk, and no material effect was found for calcium channel blockers (RR 1·02 [0·92-1·13]).
Interpretation
Blood pressure lowering is an effective strategy for the prevention of new-onset type 2 diabetes. Established pharmacological interventions, however, have qualitatively and quantitively different effects on diabetes, likely due to their differing off-target effects, with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers having the most favourable outcomes. This evidence supports the indication for selected classes of antihypertensive drugs for the prevention of diabetes, which could further refine the selection of drug choice according to an individual's clinical risk of diabetes.
Funding
British Heart Foundation, National Institute for Health Research, and Oxford Martin School.
Sources & attribution
Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis.
Nazarzadeh M, Bidel Z, Canoy D, Copland E, Wamil M, Majert J, Smith Byrne K, Sundström J, Teo K, Davis BR, Chalmers J, Pepine CJ, Dehghan A, Bennett DA, Smith GD, Rahimi K, Blood Pressure Lowering Treatment Trialists’ Collaboration.
Lancet (London, England) · 2021-11-01
DOI: 10.1016/s0140-6736(21)01920-6 ↗PubMed · 34774144 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
Disrupted daily rest-activity rhythm is linked to higher mortality in 109,365 people
Across seven observational studies with 109,365 participants, a weaker day-night activity contrast (lower relative amplitude) was associated with higher cardiovascular mortality (hazard ratio [HR] 1.50, 95% CI 1.13 to 1.98) and all-cause mortality (HR 1.46, 95% CI 1.27 to 1.68). The evidence base is small and observational, so it cannot show that improving the rhythm lowers risk, and illness may itself disturb the rhythm.
Journal of the American Heart Association
Five exercise types lowered resting blood pressure, isometric training the most
Pooling 270 randomised trials with 15,827 participants, aerobic, resistance, combined, interval and isometric training all lowered resting blood pressure compared with non-intervention controls (P<0.001 for each), with the largest fall for isometric training: 8.24 mm Hg systolic and 4.00 mm Hg diastolic. The ranking between modes is partly indirect and the trials differ, so it is not a personal prescription.
British Journal of Sports Medicine
A salt substitute lowered stroke, major cardiovascular events and death in rural China
In 20,995 people in 600 rural Chinese villages who had a history of stroke or were 60 or older with high blood pressure, a salt substitute (75% sodium chloride, 25% potassium chloride) lowered the stroke rate versus regular salt over a mean 4.74 years: 29.14 versus 33.65 events per 1000 person-years (rate ratio 0.86, 95% CI 0.77 to 0.96; P = 0.006). Death was also lower (rate ratio 0.88) and serious hyperkalemia events were not significantly higher, but the trial was open-label and set in rural China.
The New England Journal of Medicine
Apple Watch irregular-pulse alerts were rare; 34% of those tested had atrial fibrillation
Among 419,297 Apple Watch users with no known atrial fibrillation (AF), 0.52% received an irregular-pulse alert, and 34% of the 450 who returned a usable ECG patch had AF (97.5% CI 29 to 39). Alerts that coincided with patch recording matched AF with a positive predictive value of 0.84 (95% CI 0.76 to 0.92), but only 20.8% of alerted people returned a patch and nobody without an alert was monitored, so a quiet watch does not rule AF out.
The New England Journal of Medicine

